Boyd K.P., Korf B.R., Theos A. Neurofibromatosis type 1. J Am Acad Dermatol 2009;61(1):1–14. DOI: 10.1016/j.jaad.2008.12.051.
DOI: 10.1016/j.jaad.2008.12.051
Choi J., An S., Lim S.Y. Current concepts of neurofibromatosis type 1: pathophysiology and treatment. Arch Craniofac Surg 2022;23(1):6–16. DOI: 10.7181/acfs.2022.00633.
DOI: 10.7181/acfs.2022.00633
Peduto C., Zanobio M., Nigro V. et al. Neurofibromatosis type 1: pediatric aspects and review of genotype-phenotype correlations. Cancers (Basel) 2023;15(4):1217. DOI: 10.3390/cancers15041217.
DOI: 10.3390/cancers15041217
DeBella K., Szudek J., Friedman J.M. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000;105(3 Pt 1):608–14. DOI: 10.1542/peds.105.3.608.
DOI: 10.1542/peds.105.3.608
Xiong R., Lei J., Wang L. et al. Efficient analysis of adverse drug events and toxicological mechanisms of newly marketed drugs by integrating pharmacovigilance and network toxicology: selumetinib as an example. Front Pharmacol 2024;15:1432759. DOI: 10.3389/fphar.2024.1432759.
DOI: 10.3389/fphar.2024.1432759
Longo J.F., Weber S.M., Turner-Ivey B.P., Carroll S.L. Recent advances in the diagnosis and pathogenesis of neurofibromatosis type 1 (NF1)-associated peripheral nervous system neoplasms. Adv Anat Pathol 2018;25(5):353–68. DOI: 10.1097/PAP.0000000000000197.
DOI: 10.1097/PAP.0000000000000197
Bergoug M., Doudeau M., Godin F. et al. Neurofibromin structure, functions and regulation. Cells 2020;9(11):2365. DOI: 10.3390/cells9112365.
DOI: 10.3390/cells9112365
Laycock-van Spyk S., Thomas N., Cooper D.N., Upadhyaya M. Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genomics 2011;5(6):623–90. DOI: 10.1186/1479-7364-5-6-623.
DOI: 10.1186/1479-7364-5-6-623
Резолюция Экспертного совета по проблемам диагностики и лечения пациентов с плексиформными нейрофибромами. Российский журнал детской гематологии и онкологии 2021;8(2):144–52. DOI: 10.21682/2311-1267-2021-8-2-144-152.
DOI: 10.21682/2311-1267-2021-8-2-144-152
Collins-Sawaragi Y.C., Ferner R., Vassallo G. et al. Location, symptoms, and management of plexiform neurofibromas in 127 children with neurofibromatosis 1, attending the National Complex Neurofibromatosis 1 service, 2018–2019. Am J Med Genet A 2022;188(6):1723–7. DOI: 10.1002/ajmg.a.62691.
DOI: 10.1002/ajmg.a.62691
Мустафин Р.Н. Перспективы лечения нейрофиброматоза 1-го типа. Современная онкология 2022;24(2):209–15. DOI: 10.26442/18151434.2022.2.201431.
DOI: 10.26442/18151434.2022.2.201431
Suppiah S., Mansouri S., Mamatjan Y. et al. Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. Nat Commun 2023;14(1):2696. DOI: 10.1038/s41467-023-38432-6.
DOI: 10.1038/s41467-023-38432-6
Пивоварова А.М., Дорофеева М.Ю., Забродина А.Р. и др. Лекарственная терапия плексиформных нейрофибром при нейрофиброматозе 1-го типа. Возможные нежелательные явления и их коррекция. Русский журнал детской неврологии 2024;19(2):8–19. DOI: 10.17650/2073-8803-2024-19-2-8-19.
DOI: 10.17650/2073-8803-2024-19-2-8-19
Tamura R. Current understanding of neurofibromatosis type 1, 2, and schwannomatosis. Int J Mol Sci 2021;22(11):5850. DOI: 10.3390/ijms22115850.
DOI: 10.3390/ijms22115850
Gross A.M., Wolters P., Baldwin A. et al. SPRINT: phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN). Pediatr Oncol 2018;36(15):10503. DOI: 10.1200/JCO.2018.36.15_suppl.10503.
DOI: 10.1200/JCO.2018.36.15_suppl.10503
Gross A.M., Wolters P.L., Dombi E. et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 2020;382(15):1430–42. DOI: 10.1056/NEJMoa1912735..
DOI: 10.1056/NEJMoa1912735
Campagne O., Yeo K.K., Fangusaro J., Stewart C.F. Clinical pharmacokinetics and pharmacodynamics of selumetinib. Clin Pharmacokinet 2021;60(3):283–303. DOI: 10.1007/s40262-020-00967-y.
DOI: 10.1007/s40262-020-00967-y
Dombi E., Baldwin A., Marcus L.J. et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med 2016;375(26):2550–60. DOI: 10.1056/NEJMoa1605943.
DOI: 10.1056/NEJMoa1605943
Luu M., Boone S.L., Patel J. et al. Higher severity grade of erlotinibinduced rash is associated with lower skin phototype. Clin Exp Dermatol 2011;36(7):733–8. DOI: 10.1111/j.1365-2230.2011.04117.
DOI: 10.1111/j.1365-2230.2011.04117
Borgia P., Piccolo G., Santangelo A. et al. Dermatologic effects of selumetinib in pediatric patients with neurofibromatosis type 1: clinical challenges and therapeutic management. J Clin Med 2024;13(6):1792. DOI: 10.3390/jcm13061792.
DOI: 10.3390/jcm13061792
Boull C.L., Gardeen S., Abdali T. et al. Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: a multicenter study. J Am Acad Dermatol 2020;84(6):1554–61. DOI: 10.1016/j.jaad.2020.07.044.
DOI: 10.1016/j.jaad.2020.07.044
Akilli Öztürk Ö., Pakula H., Chmielowiec J. et al. Gab1 and Mapk signaling are essential in the hair cycle and hair follicle stem cell quiescence. Cell Rep 2015;13(3):561–72. DOI: 10.1016/j.celrep.2015.09.015.
DOI: 10.1016/j.celrep.2015.09.015
Palmeiro A.G., Silva L., Pimentel B. et al. MEK inhibitor-induced paronychia in a paediatric population: a tertiary centre experience. Australas J Dermatol 2023;64(3):e245–51. DOI: 10.1111/ajd.14079.
DOI: 10.1111/ajd.14079
Abdel-Rahman O., ElHalawani H., Ahmed H. Risk of selected cardiovascular toxicities in patients with cancer treated with MEK inhibitors: a comparative systematic review and meta-analysis. J Glob Oncol 2015;1(2):73–82. DOI: 10.1200/JGO.2015.000802.
DOI: 10.1200/JGO.2015.000802
Australian product information. Koselugo® (selumetinib sulfate) capsules. Alexion Pharmaceuticals, Inc. PM-2020-05290-1-4 FINAL. 2024.
Glen C., Tan Y.Y., Waterston A. et al. Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology state-of-the-art review. JACC CardioOncol 2022;4(1):1–18. DOI: 10.1016/j.jaccao.2022.01.096.
DOI: 10.1016/j.jaccao.2022.01.096
Avery R.A., Trimboli-Heidler C., Kilburn L.B. Separation of outer retinal layers secondary to selumetinib. J AAPOS 2016;20(3):268–71. DOI: 10.1016/j.jaapos.2016.01.012.
DOI: 10.1016/j.jaapos.2016.01.012
Azizi A.A., Hargrave D., Passos J. et al. Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Neurooncol Pract 2024;11(5):515–31. DOI: 10.1093/nop/npae038.
DOI: 10.1093/nop/npae038
Jeng-Miller K.W., Miller M.A., Heier J.S. Ocular effects of MEK inhibitor therapy: literature review, clinical presentation, and best practices for mitigation. Oncologist 2024;29(5):e616–21. DOI: 10.1093/oncolo/oyae014.
DOI: 10.1093/oncolo/oyae014
Hummel L., Ameri M., Alqahtani S. et al. Incidence of ophthalmological complications in NF-1 patients treated with MEK inhibitors. Curr Oncol 2024;31(5):2644–9. DOI: 10.3390/curroncol31050199.
DOI: 10.3390/curroncol31050199
Coltin H., Perreault S., Larouche V. et al. Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: a national real-world case series. Pediatr Blood Cancer 2022;69(8):e29633. DOI: 10.1002/pbc.29633.
DOI: 10.1002/pbc.29633
Yang Y., Liu Y.H., Sun X. et al. Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and metaanalysis of clinical trials. Curr Med Res Opin 2017;33(9):1663–75. DOI: 10.1080/03007995.2017.1349657.
DOI: 10.1080/03007995.2017.1349657
Общая характеристика лекарственного препарата Коселуго®️ (капсулы, 10 мг, 25 мг). Регистрационное удостоверение ЛП- №(005053)-(РГ-RU) от 25.09.2024.
Kang E., Yoon H.M., Lee B.H. Neurofibromatosis type I: points to be considered by general pediatricians. Clin Exp Pediatr 2021;64(4):149–56. DOI: 10.3345/cep.2020.00871.
DOI: 10.3345/cep.2020.00871
Freites-Martinez A., Santana N., Arias-Santiago S., Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE – version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 2021;112(1):90–2. DOI: 10.1016/j.ad.2019.05.009.
DOI: 10.1016/j.ad.2019.05.009
Kim H., Yoon H.M., Kim E.K. et al. Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma. Neuro Oncol 2024;26(12): 2352–63. DOI: 10.1093/neuonc/noae121.
DOI: 10.1093/neuonc/noae121
Yoshida Y., Tozawa K., Koto R. et al. Patient characteristics, treatment patterns, healthcare resource utilization, and costs among patients diagnosed with neurofibromatosis type 1 with and without plexiform neurofibromas in Japan. Curr Med Res Opin 2024;40(4): 723–31. DOI: 10.1080/03007995.2024.2322698.
DOI: 10.1080/03007995.2024.2322698